Lilly: New phase 3b data for Taltz and Zepbound together vs Taltz alone
TradeXchange reports Lilly’s phase 3b results on Taltz and Zepbound together, showing broader biomarker changes versus Taltz alone, in adults with psoriasis and obesity.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Lilly says exploratory Taltz-Zepbound data broaden biomarker changes
Eli Lilly said exploratory Phase 3b data from the TOGETHER-PsO study showed broader biomarker changes with Taltz and Zepbound than with Taltz alone in adults with psoriasis and obesity. The company said the findings add to previously reported results on skin clearance and weight reduction.